[Therapeutic conflict in patients with COVID-19 and glaucoma].
Identifieur interne : 000915 ( Main/Exploration ); précédent : 000914; suivant : 000916[Therapeutic conflict in patients with COVID-19 and glaucoma].
Auteurs : Elena Millá Gri [Espagne] ; María Jesús Muniesa Royo [Espagne] ; Marta Pazos L Pez [Espagne]Source :
- Medicina clinica [ 1578-8989 ] ; 2020.
Descripteurs français
- KwdFr :
- Antagonistes bêta-adrénergiques (effets indésirables), Antipaludiques (effets indésirables), Betacoronavirus (MeSH), Bradycardie (induit chimiquement), Glaucome à angle ouvert (traitement médicamenteux), Humains (MeSH), Hydroxychloroquine (effets indésirables), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Timolol (effets indésirables).
- MESH :
- effets indésirables : Antagonistes bêta-adrénergiques, Antipaludiques, Hydroxychloroquine, Timolol.
- induit chimiquement : Bradycardie.
- traitement médicamenteux : Glaucome à angle ouvert, Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Betacoronavirus, Humains, Pandémies.
English descriptors
- KwdEn :
- Adrenergic beta-Antagonists (adverse effects), Antimalarials (adverse effects), Betacoronavirus (MeSH), Bioaccumulation (MeSH), Bradycardia (chemically induced), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Glaucoma, Open-Angle (drug therapy), Humans (MeSH), Hydroxychloroquine (adverse effects), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), SARS-CoV-2 (MeSH), Timolol (adverse effects).
- MESH :
- chemical , adverse effects : Adrenergic beta-Antagonists, Antimalarials, Hydroxychloroquine, Timolol.
- chemically induced : Bradycardia.
- drug therapy : Coronavirus Infections, Glaucoma, Open-Angle, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, Bioaccumulation, COVID-19, Humans, Pandemics, SARS-CoV-2.
DOI: 10.1016/j.medcli.2020.05.020
PubMed: 32591182
PubMed Central: PMC7274610
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Therapeutic conflict in patients with COVID-19 and glaucoma].</title><author><name sortKey="Milla Gri, Elena" sort="Milla Gri, Elena" uniqKey="Milla Gri E" first="Elena" last="Millá Gri">Elena Millá Gri</name><affiliation wicri:level="3"><nlm:affiliation>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona, España. Electronic address: millagrinoelena@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Muniesa Royo, Maria Jesus" sort="Muniesa Royo, Maria Jesus" uniqKey="Muniesa Royo M" first="María Jesús" last="Muniesa Royo">María Jesús Muniesa Royo</name><affiliation wicri:level="3"><nlm:affiliation>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Pazos L Pez, Marta" sort="Pazos L Pez, Marta" uniqKey="Pazos L Pez M" first="Marta" last="Pazos L Pez">Marta Pazos L Pez</name><affiliation wicri:level="3"><nlm:affiliation>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32591182</idno><idno type="pmid">32591182</idno><idno type="doi">10.1016/j.medcli.2020.05.020</idno><idno type="pmc">PMC7274610</idno><idno type="wicri:Area/Main/Corpus">001295</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001295</idno><idno type="wicri:Area/Main/Curation">001295</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001295</idno><idno type="wicri:Area/Main/Exploration">001295</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Therapeutic conflict in patients with COVID-19 and glaucoma].</title><author><name sortKey="Milla Gri, Elena" sort="Milla Gri, Elena" uniqKey="Milla Gri E" first="Elena" last="Millá Gri">Elena Millá Gri</name><affiliation wicri:level="3"><nlm:affiliation>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona, España. Electronic address: millagrinoelena@gmail.com.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Muniesa Royo, Maria Jesus" sort="Muniesa Royo, Maria Jesus" uniqKey="Muniesa Royo M" first="María Jesús" last="Muniesa Royo">María Jesús Muniesa Royo</name><affiliation wicri:level="3"><nlm:affiliation>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Pazos L Pez, Marta" sort="Pazos L Pez, Marta" uniqKey="Pazos L Pez M" first="Marta" last="Pazos L Pez">Marta Pazos L Pez</name><affiliation wicri:level="3"><nlm:affiliation>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></analytic><series><title level="j">Medicina clinica</title><idno type="eISSN">1578-8989</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic beta-Antagonists (adverse effects)</term><term>Antimalarials (adverse effects)</term><term>Betacoronavirus (MeSH)</term><term>Bioaccumulation (MeSH)</term><term>Bradycardia (chemically induced)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Glaucoma, Open-Angle (drug therapy)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (adverse effects)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>SARS-CoV-2 (MeSH)</term><term>Timolol (adverse effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antagonistes bêta-adrénergiques (effets indésirables)</term><term>Antipaludiques (effets indésirables)</term><term>Betacoronavirus (MeSH)</term><term>Bradycardie (induit chimiquement)</term><term>Glaucome à angle ouvert (traitement médicamenteux)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (effets indésirables)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (épidémiologie)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (épidémiologie)</term><term>Timolol (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adrenergic beta-Antagonists</term><term>Antimalarials</term><term>Hydroxychloroquine</term><term>Timolol</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Bradycardia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Glaucoma, Open-Angle</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antagonistes bêta-adrénergiques</term><term>Antipaludiques</term><term>Hydroxychloroquine</term><term>Timolol</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Bradycardie</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Glaucome à angle ouvert</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Bioaccumulation</term><term>COVID-19</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term><term>Humains</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32591182</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8989</ISSN><JournalIssue CitedMedium="Internet"><Volume>155</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>08</Month><Day>28</Day></PubDate></JournalIssue><Title>Medicina clinica</Title><ISOAbbreviation>Med Clin (Barc)</ISOAbbreviation></Journal><ArticleTitle>[Therapeutic conflict in patients with COVID-19 and glaucoma].</ArticleTitle><Pagination><MedlinePgn>182</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0025-7753(20)30347-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medcli.2020.05.020</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Millá Griñó</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona, España. Electronic address: millagrinoelena@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muniesa Royo</LastName><ForeName>María Jesús</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pazos López</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut Clínic d'Oftalmología, Hospital Clínic, Barcelona, España.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><VernacularTitle>Conflicto terapéutico en pacientes con COVID-19 y glaucoma.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Clin (Barc)</MedlineTA><NlmUniqueID>0376377</NlmUniqueID><ISSNLinking>0025-7753</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>817W3C6175</RegistryNumber><NameOfSubstance UI="D013999">Timolol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000319" MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000081482" MajorTopicYN="N">Bioaccumulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001919" MajorTopicYN="N">Bradycardia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005902" MajorTopicYN="N">Glaucoma, Open-Angle</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013999" MajorTopicYN="N">Timolol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>05</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32591182</ArticleId><ArticleId IdType="pii">S0025-7753(20)30347-X</ArticleId><ArticleId IdType="doi">10.1016/j.medcli.2020.05.020</ArticleId><ArticleId IdType="pmc">PMC7274610</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Clin Pharmacol. 2000 Jun;49(6):549-54</Citation><ArticleIdList><ArticleId IdType="pubmed">10848718</ArticleId></ArticleIdList></Reference><Reference><Citation>J Ophthalmol. 2015;2015:567387</Citation><ArticleIdList><ArticleId IdType="pubmed">25874117</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Pharmacol Toxicol. 2019 Dec 2;20(1):73</Citation><ArticleIdList><ArticleId IdType="pubmed">31791399</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Cardiol. 2020 Jun;36(6):948-951</Citation><ArticleIdList><ArticleId IdType="pubmed">32299753</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><country name="Espagne"><region name="Catalogne"><name sortKey="Milla Gri, Elena" sort="Milla Gri, Elena" uniqKey="Milla Gri E" first="Elena" last="Millá Gri">Elena Millá Gri</name></region><name sortKey="Muniesa Royo, Maria Jesus" sort="Muniesa Royo, Maria Jesus" uniqKey="Muniesa Royo M" first="María Jesús" last="Muniesa Royo">María Jesús Muniesa Royo</name><name sortKey="Pazos L Pez, Marta" sort="Pazos L Pez, Marta" uniqKey="Pazos L Pez M" first="Marta" last="Pazos L Pez">Marta Pazos L Pez</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000915 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000915 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32591182
|texte= [Therapeutic conflict in patients with COVID-19 and glaucoma].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32591182" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |